Table 1:
Patient Demographics and Clinical Characteristics by CPM Status in AllT4a Cohort
| Characteristics | Categories | Totalb N=23943 | UM N=19641 | CPM N=4302 | P-value |
|---|---|---|---|---|---|
| Age, year | [≥65] | 8930 (37.3) | 8219 (41.8) | 711 (16.5) | <0.001 |
| [50–64] | 9134 (38.1) | 7312 (37.2) | 1822 (42.4) | ||
| [40–49] | 4225 (17.6) | 3049 (15.5) | 1176 (27.3) | ||
| [18–39] | 1654 (6.9) | 1061 (5.4) | 593 (13.8) | ||
| Race | White | 18841 (78.7) | 15159 (77.2) | 3682 (85.6) | <0.001 |
| Black | 4023 (16.8) | 3535 (18.0) | 488 (11.3) | ||
| Other/unknown | 1079 (4.5) | 947 (4.8) | 132 (3.1) | ||
| Ethnicity | H/L | 1505 (6.7) | 1301 (7.1) | 204 (5.0) | <0.001 |
| Non-H/L | 20958(87.5) | 17116(87.1) | 3842(89.3) | ||
| Education: % of No HSDc | [≥21] | 4551 (19.3) | 3916 (20.2) | 635 (14.9) | <0.001 |
| [13–20.9] | 6447 (27.3) | 5390 (27.8) | 1057 (24.8) | ||
| [7–12.9] | 7491 (31.7) | 6018 (31.1) | 1473 (34.5) | ||
| [< 7] | 5147 (21.8) | 4047 (20.9) | 1100 (25.8) | ||
| Insurance status | None | 1181 (4.9) | 1016 (5.2) | 165 (3.8) | <0.001 |
| Medicare | 8593 (35.9) | 7838 (39.9) | 755 (17.5) | ||
| Medicaid | 2964 (12.4) | 2444 (12.4) | 520 (12.1) | ||
| Government | 188 (0.8) | 141 (0.7) | 47 (1.1) | ||
| Private/MC | 10684 (44.6) | 7924 (40.3) | 2760 (64.2) | ||
| Unknown | 333 (1.4) | 278 (1.4) | 55 (1.3) | ||
| Facility type | CCP | 2772 (12.4) | 2426 (13.1) | 346 (9.3) | <0.001 |
| CCCP | 10398 (45.7) | 8587 (46.2) | 1811 (48.8) | ||
| INCP | 2356 (10.6) | 1891 (10.2) | 465 (12.5) | ||
| Academic/Research | 6763 (30.3) | 5676 (30.5) | 1087 (29.3) | ||
| Charlson/Deyo score | 0 | 19433 (81.2) | 15728 (80.1) | 3705 (86.1) | <0.001 |
| 1 | 3603 (15.0) | 3094 (15.8) | 509 (11.8) | ||
| 2 | 907 (3.8) | 819 (4.2) | 88 (2.0) | ||
| Tumor size, mm | [>20] | 21157 (88.4) | 17474 (89.0) | 3683 (85.6) | <0.001 |
| [≤20] | 2786 (11.6) | 2167 (11.0) | 619 (14.4) | ||
| LVI | Absent | 4272 (17.8) | 3328 (16.9) | 944 (21.9) | <0.001 |
| Present | 5262 (22.0) | 4177 (21.3) | 1085 (25.2) | ||
| NA | 14409 (60.2) | 12136 (61.8) | 2273 (52.8) | ||
| Clinical AJCC N | 0 | 6652 (29.7) | 5618 (30.7) | 1034 (25.2) | <0.001 |
| 1 | 9427 (42.0) | 7469 (40.8) | 1958 (47.7) | ||
| 2 | 4044 (18.0) | 3362 (18.3) | 682 (16.6) | ||
| 3 | 2309 (10.3) | 1877 (10.2) | 432 (10.5) | ||
| Clinical AJCC T | T4abc | 9824 (41.0) | 8349 (42.5) | 1475 (34.3) | <0.001 |
| T4d | 8321 (34.8) | 6322 (32.4) | 1949 (45.3) | ||
| T4 NOS | 5798 (24.2) | 4920 (25.0) | 878 (20.4) | ||
| ER Status | Negative | 8978 (37.5) | 7264 (37.0) | 1714 (39.8) | |
| Positive | 14178 (59.2) | 11688 (59.5) | 2490 (57.9) | <0.001 | |
| Unknown | 787(3.3) | 689(3.5) | 98(2.3) | ||
| PR Status | Negative | 11571 (48.3) | 9384 (47.8) | 2187 (50.8) | <0.001 |
| Positive | 11494 (48.0) | 9492 (48.3) | 2002 (46.5) | ||
| Unknown | 878 (3.7) | 765 (3.9) | 113 (2.6) | ||
| HER2 Statusd | Negative | 5484 (23.1) | 4350 (22.4) | 5484 (23.1) | |
| Positive | 2405 (10.2) | 1810 (9.3) | 2405 (10.2) | <0.001 | |
| Unknown | 16054(67.1) | 13481(68.6) | 2573(59.8) | ||
| Margins | Negative | 20834 (87.0) | 16911 (86.1) | 3923 (91.2) | <0.001 |
| Positive | 2688 (11.2) | 2363 (12.0) | 325 (7.6) | ||
| Chemotherapy | None | 1716(7.2) | 1659(8.4) | 57(1.3) | <0.001 |
| Neoadjuvant | 13970(58.3) | 10794(55.0) | 3176(73.8) | ||
| Adjuvant | 4126(17.2) | 3635(18.5) | 491(11.4) | ||
| Unknown | 4131(17.3) | 3553(18.1) | 578(13.4) | ||
| PMRT | None | 8320(34.7) | 7257(36.9) | 1063(24.7) | <0.001 |
| Yes | 15243(64.5) | 12053 (62.2) | 3190 (74.9) | <0.001 | |
| Unknown | 1045(4.4) | 912(3.7) | 133(2.0) | ||
| Endocrine | None | 9831(41.1) | 8137(41.4) | 1694(39.4) | 0.031 |
| Therapy | Yes | 11703(48.9) | 9502(48.4) | 2201(51.2) | |
| Unknown | 2409(10.0) | 1997(10.2) | 407(9.5) | ||
| Immunotherapy | None | 22262(93.0) | 18358(93.5) | 3904(90.7) | <0.001 |
| Yes | 1345(5.6) | 989(5.0) | 356(8.3) | ||
| Unknown | 336(1.4) | 294(1.5) | 42(1.0) | ||
AllT4 = Tabc+T4+NOS (not otherwise specified)
Column % may not add up to 100 due to missing information
No HSD: Percentage of no high school degree by zip codes
Routine HER2neu status was available after 2010
CPM, contralateral prophylactic mastectomy; UM, unilateral mastectomy; H/L, Hispanic/Latino; HSD, high-school diploma; CCP, community cancer program; CCCP indicates comprehensive community cancer program; INCP, integrated network cancer program; LVI, lymphovascular invasion; NA, not available; AJCC, American Joint Committee on Cancer; NOS, not otherwise specified; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; PMRT Post-mastectomy radiotherapy